News
CDMO
6.39
-1.99%
-0.13
Laughing Water Capital Q1 2024 Letter
Seeking Alpha · 1d ago
UPDATE 1-EnQuest selling stake in North Sea Golden Eagle oilfield, sources say
EnQuest selling stake in North Sea Golden Eagle oilfield, sources say. Britain's EnQuest is looking to sell its 27% stake in the Golden Eagle field in the British North Sea. The company bought the stake from Suncor in 2021 for $325 million. EnQuest has struggled in recent years with high debt levels.
Reuters · 3d ago
Analysts’ Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)
TipRanks · 3d ago
Weekly Report: what happened at CDMO last week (0408-0412)?
Weekly Report · 4d ago
Avid Bioservices: Statement of changes in beneficial ownership of securities
Press release · 04/12 02:04
Weekly Report: what happened at CDMO last week (0401-0405)?
Weekly Report · 04/08 09:42
Central Banks Rule Next Week
Monday U.S. Featured Earnings include Avid Bioservices, Inc. And Delta Air Lines. The total monthly value of building permits in Canada increased 13.5% in January to $10.8 billion. The Bank of Canada is expected to make a decision on the interest rate in April.
Barchart · 04/05 15:35
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
TipRanks · 04/01 12:36
Weekly Report: what happened at CDMO last week (0325-0329)?
Weekly Report · 04/01 09:42
Avid Bioservices Inc <CDMO.OQ> expected to post a loss of 5 cents a share - Earnings Preview
Avid Bioservices Inc expected to post a loss of 5 cents a share. The company is expected to report a 12.0% decrease in quarterly revenue to $33.452 million from $38.02 million.
Reuters · 03/29 21:14
Weekly Report: what happened at CDMO last week (0318-0322)?
Weekly Report · 03/25 09:43
Weekly Report: what happened at CDMO last week (0311-0315)?
Weekly Report · 03/18 09:42
Avid Bioservices Inc <CDMO.OQ> expected to post a loss of 5 cents a share - Earnings Preview
Avid Bioservices Inc expected to post a loss of 5 cents a share - Earnings Preview. The company is expected to report a 12.0% decrease in quarterly revenue to $33.452 million.
Reuters · 03/15 21:24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
Glancy Prongay & Murray LLP has commenced an investigation on behalf of Avid Bioservices, Inc. Investors concerning the Company’s possible violations of the federal securities laws. On March 6, 2024, Avid disclosed that it received an acceleration notice from a holder of its senior notes. Avid's stock price fell 30.6% on March 7, 2024.
Barchart · 03/14 13:12
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Avid Bioservices, Inc. Investors concerning the Company’s possible violations of federal securities laws. On March 6, 2024, Avid disclosed that it received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026. The Company also disclosed it may be unable to timely file its first quarter 2024 financial results. Avid's stock price fell $2.69, or 30.6%, on March 7, 2024.
Barchart · 03/13 19:36
The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. On behalf of investors. Avid’s stock price fell $2.69, or 30.6%, to close at $6.10 per share on March 7, 2024. The Company received an acceleration notice of possible violations of federal securities laws.
Barchart · 03/13 13:40
Avid Bioservices Is Maintained at Overweight by Stephens & Co.
Dow Jones · 03/11 15:10
Avid Bioservices Price Target Cut to $12.00/Share From $15.00 by Stephens & Co.
Dow Jones · 03/11 15:10
Stephens & Co. Maintains Overweight on Avid Bioservices, Lowers Price Target to $12
Benzinga · 03/11 15:00
Weekly Report: what happened at CDMO last week (0304-0308)?
Weekly Report · 03/11 09:41
More
Webull provides a variety of real-time CDMO stock news. You can receive the latest news about Avid Bioservices through multiple platforms. This information may help you make smarter investment decisions.
About CDMO
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company’s services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.